Form 4: CG Oncology Director Sells Shares After Option Exercise

CG Oncology Director James Mulay exercised stock options and subsequently sold 5,903 shares of common stock for $43.99 per share.

Summary

• Director James Mulay exercised 5,903 stock options at an exercise price of $3.72 per share on October 9, 2025.
• Immediately following the exercise, Mulay sold all 5,903 shares of common stock at a price of $43.99 per share on the same date.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
• Following these transactions, Mulay beneficially owns 1,962 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The filing reports a pre-planned insider transaction (option exercise and sale) which is neutral in sentiment, reflecting a director monetizing vested equity rather than a specific positive or negative company event.

Positives

• Director Mulay realized a significant gain from exercising options at $3.72 and selling shares at $43.99.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating planned activity rather than a reaction to immediate news.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market.
• The sale reduced Director Mulay's direct beneficial ownership of common stock to zero for the transacted shares.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the insider sale as a signal, though mitigated by the pre-arranged Rule 10b5-1 plan.

Key Dates

Recommendation

This Form 4 reports a pre-scheduled insider transaction where a director exercised vested stock options and immediately sold the acquired shares. Such transactions, executed under a Rule 10b5-1 trading plan, are generally considered routine and do not typically signal a change in the company's fundamental outlook or warrant an immediate adjustment to an investment recommendation. The sale monetizes existing equity rather than indicating a lack of confidence.

Keywords

CG Oncology, CGON, Insider Trading, Form 4, Stock Option, Share Sale, Director, James Mulay, 10b5-1 Plan